← All trials
NCT05439629
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 30, 2022
- Primary completion
- Jun 30, 2024
- Completion date
- Jun 30, 2025
- First posted
- Jun 30, 2022
- Last posted
- Jun 30, 2022
- Enrollment
- 488
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- BiotheraLead sponsor
- Guizhou Medical UniversityOverall official - principal investigator
- Inner Mongolia Medical UniversityOverall official - principal investigator
- Nantong UniversityOverall official - principal investigator
- Wenzhou Medical UniversityOverall official - principal investigator
- Capital Medical UniversityOverall official - principal investigator
- Peking UniversityOverall official - principal investigator
- Peking UniversityOverall official - principal investigator
- Fujian Medical UniversityOverall official - principal investigator
- Sun Yat-Sen UniversityOverall official - principal investigator
- Hebei UniversityOverall official - principal investigator
- Fudan UniversityOverall official - principal investigator
- Peking UniversityOverall official - principal investigator
- People's Hospital of QuzhouOverall official - principal investigator
- Shanxi Medical UniversityOverall official - principal investigator
- Shanghai Oriental HospitalOverall official - principal investigator
- Shanghai University of Traditional Chinese MedicineOverall official - principal investigator
- Shenzhen UniversityOverall official - principal investigator
- Sun Yat-Sen UniversityOverall official - principal investigator
- Wenzhou Medical UniversityOverall official - principal investigator
- Guangzhou UniversityOverall official - principal investigator
- Zhengzhou UniversityOverall official - principal investigator
- Jinlin UniversityOverall official - principal investigator
- China Medical UniversityOverall official - principal investigator
- Jiao Tong UniversityOverall official - principal investigator
- Chongqing Medical UniversityOverall official - principal investigator
- Anhui Medical UniversityOverall official - principal investigator
- Central South UniversityOverall official - principal investigator
- Shanghai Xuhui District Central HospitalOverall official - principal investigator
- Qingdao UniversityOverall official - principal investigator
- Zhejiang UniversityOverall official - principal investigator
- Zunyi Medical CollegeOverall official - principal investigator
- Nantong UniversityOfficial
- Shanghai University of Traditional Chinese MedicineOfficial
- Inner Mongolia Medical UniversityOfficial
- Qingdao UniversityOfficial
- Zunyi Medical CollegeOfficial
- Shanxi Medical UniversityOfficial
- Jinlin UniversityOfficial
- China Medical UniversityOfficial
- Shanghai Xuhui District Central HospitalOfficial
- Zhejiang UniversityOfficial
- Peking UniversityOfficial
- Peking UniversityOfficial
- Peking UniversityOfficial
- Anhui Medical UniversityOfficial
- People's Hospital of QuzhouOfficial
- Fujian Medical UniversityOfficial
- Hebei UniversityOfficial
- Zhengzhou UniversityOfficial
- Chongqing Medical UniversityOfficial
- Guangzhou UniversityOfficial
- Sun Yat-Sen UniversityOfficial
- Sun Yat-Sen UniversityOfficial
- Jiao Tong UniversityOfficial
- Central South UniversityOfficial
- Guizhou Medical UniversityOfficial
- Fudan UniversityOfficial
- Wenzhou Medical UniversityOfficial
- Capital Medical UniversityOfficial
- Shanghai Oriental HospitalOfficial
- Shenzhen UniversityOfficial
- Wenzhou Medical UniversityOfficial
- Luoyang third people's HospitalOfficial
- Ningbo Eye HospitalOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.